Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 12, 2013, Pages

  Eftimov, Filip ^a   Winer, John B ^b   Vermeulen, Marinus ^a   de Haan, Rob ^a   van Schaik, Ivo N ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; METHYLPREDNISOLONE; PLACEBO; PREDNISOLONE;

CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY; DISABILITY; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; PLASMA EXCHANGE; POLYRADICULONEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RANKIN SCALE; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW;

EID: 84992738765     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD001797.pub3     Document Type: Review

References (71)

1. Dyck PJ, Litchy WJ, Kratz KM, Suarez GA, Low PA, Pineda AA, et al.A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Annals of Neurology 1994;36(6):838-45. [PUBMED: 7998769]
2. Hahn AF, Bolton CF, Zochodne D, Feasby TE. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study. Brain 1996;119(Part 4):1067-77. [PUBMED: 8813271]
3. Hughes R, Bensa S, Willison HJ, Van den Bergh P, Comi G, Illa I, et al.Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Annals of Neurology 2001;50(2):195-201. [PUBMED: 11506402]
4. Hughes RA, Donofrio P, Bril V, Dalakas MC, Deng C, Hanna K, et al.ICE Study Group. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE Study): a randomised placebo-controlled trial. Lancet Neurology 2008;7(2):136-44. [PUBMED: 18178525]
5. Mendell JR, Barohn RJ, Freimer ML, Kissel JT, King WM, Nagaraja HN, et al.Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2001;56(4):445-9. [PUBMED: 11222785]
6. Nobile-Orazio N, Cocito D, Jann S, Uncini A, Beghi E, Messina P, et al.IMC Trial Group. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial. Lancet Neurology 2012;11(6):493-502. [PUBMED: 22578914]
7. Thompson N, Choudhary P, Hughes RAC, Quinlivan RM. A novel trial design to study the effect of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. Journal of Neurology 1996;243(3):280-5. [PUBMED: 8936360]
8. Vermeulen M, van Doorn PA, Brand A, Strengers PF, Jennekens FG, Busch HF. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. Journal of Neurology, Neurosurgery & Psychiatry 1993;56(1):36-9. [PUBMED: 8429321]
9. Baba M, Ogawa M, Matsunaga M. Treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). Clinical Neurology 1996;36(12):1336-7.
10. Curro DB, Tezzon F. High-dose intravenous gammaglobulin for chronic inflammatory demyelinating polyneuropathy. Italian Journal of Neurological Sciences 1987;8(4):321-6.
11. Dalakas MC, Quarles RH, Farrer RG, Dambrosia J, Soueidan S, Stein DP, et al.A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Annals of Neurology 1996;40(5):792-5.
12. Hankey GJ, Todd AAM, Yap PL, Warlow CP. An 'n of 1' trial of intravenous immunoglobulin treatment for chronic inflammatory demyelinating polyneuropathy. Journal of Neurology, Neurosurgery & Psychiatry 1994;57(9):1137.
13. Kubori T, Mezaki T, Kaji R, Kimura J, Hamaguchi K, Hirayama K, et al.The clinical usefulness of high-dose intravenous immunoglobulin therapy for chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy. Brain & Nerve 1999;51(2):127-35.
14. van Doorn PA, Brand A, Strengers PF, Meulstee J, Vermeulen M. High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study. Neurology 1990;40(2):209-12.
15. Zinman LH, Sutton D, Ng E, Nwe P, Ngo M, Bril V. A pilot study to compare the use of Excorim staphylococcal protein immunoadsorption system and IVIG in chronic inflammatory demyelinating polyneuropathy. Transfusion and Apheresis Science 2005;33(3):317-324.
16. NCT01225276 . Safety and efficacy study of three different dosages of NewGam in patients with CIDP (POINT). http://clinicaltrials.gov/show/NCT01225276 (accessed 4 December 2013).
17. Ad hoc subcommittee of the American Academy of Neurology AIDS Task Force. Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Neurology 1991;41(5):617-8.
18. Barohn RJ, Kissel JT, Warmolts JR, Mendell JR. Chronic inflammatory demyelinating polyradiculoneuropathy. Clinical characteristics, course, and recommendations for diagnostic criteria. Archives of Neurology 1989;46(8):878-84.
19. Briellmann RS, Nydegger UE, Sturzenegger M, Fierz L, Hess CW, Hauser SP. Long term treatment of chronic inflammatory demyelinating polyradiculoneuropathy: combinations of corticosteroids, plasma exchange, and intravenous immunoglobulin. European Neurology 1998;39(3):190-1.
20. Chiò A, Cocito D, Bottacchi E, Buffa C, Leone M, Plano F, et al.Idiopathic chronic inflammatory demyelinating polyneuropathy: an epidemiological study in Italy. Journal of Neurology, Neurosurgery & Psychiatry 2007;78(12):1349-53.
21. Cornblath DR, Chaudhry V, Griffin JW. Treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulin. Annals of Neurology 1991;30(1):104-6.
22. de Haan R, Aaronson N, Limburg M, Hewer RL, van Crevel H. Measuring quality of life in stroke. Stroke 1993;24(2):320-7.
23. Donaghy M, Earl CJ. Ocular palsy preceding chronic relapsing polyneuropathy by several weeks. Annals of Neurology 1985;17(1):49-50.
24. Duhem C, Dicato MA, Ries F. Side-effects of intravenous immune globulins. Clinical & Experimental Immunology 1994;97(Suppl 1):79-83.
25. Dyck PJ, O'Brien P, Oviatt KF. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Annals of Neurology 1982;11(2):136-41.
26. Dyck PJ, Daube J, O'Brien P, Pineda A, Low PA, Windebank AJ, et al.Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. New England Journal of Medicine 1986;314(8):461-5.
27. Dyck PJ, Karnes JL, O'Brien PC, Litchy WJ, Low PA, Melton LJ. The Rochester diabetic neuropathy study: reassessment of tests and criteria for diagnosis and staged severity. Neurology 1992;42(6):1164-70.
28. Dyck PJ, Prineas JW, Pollard JD. Chronic inflammatory demyelinating polyradiculoneuropathy. In: Thomas PK, Griffin J, Low PA, editor(s). Peripheral Neuropathy. Philadelphia: W.B. Saunders Company, 1993:1498-17.
29. Elbourne DR, Altman DG, Higgins JP, Curtin F, Wothington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
30. Faed JM, Day B, Pollock M, Taylor PK, Nukada H, Hammond-Tooke GD. High-dose intravenous human immunoglobulin in chronic inflammatory demyelinating polyneuropathy. Neurology 1989;39(3):422-5.
31. Feasby TE. Inflammatory demyelinating polyneuropathies. Neurologic Clinics 1992;10(3):651-70.
32. The Guillain-Barré syndrome study group. Plasmapheresis and acute Guillain-Barré syndrome. Neurology 1985;35(8):1096-104.
33. Gillespie LD, Gillespie WJ, Cumming R, Lamb SE, Rowe BH. Interventions to reduce the incidence of falling in the elderly. Cochrane Database of Systematic Reviews 1998, Issue 4. [DOI: ]
34. Gross MLP, Thomas PK. The treatment of chronic relapsing and chronic progressive idiopathic inflammatory polyneuropathy by plasma exchange. Journal of the Neurological Sciences 1981;52(1):69-78.
35. Hahn AF. Treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulin. Neurology 1998;51(6 Suppl 5):16-21.
36. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions [updated February 2008]. Version 5.0.0. Available from www.cochrane-handbook.org: The Cochrane Collaboration, 2008.
37. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
38. Ioannidis JPA, Cappelleri JC, Lau J, Skolnik PR, Melville B, Chalmets TC, et al.Early or deferred zidovudine therapy in HIV-infected patients without an AIDS-defining illness. Annals of Internal Medicine 1995;122:856-66.
39. Kazatchkine MD, Kaveri SV. Immunomodulation of Autoimmune and Inflammatory Disease with Intravenous Immune Globulin. New England Journal of Medicine 2001;345(10):747-55.
40. Latov N, Deng C, Dalakas MC, Bril V, Donofrio P, Hanna K, et al.Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. Archives of Neurology 2010;67(7):802-7.
41. Laughlin RS, Dyck PJ, Melton LJ III, Leibson C, Ransom J, Dyck PJ. Incidence and prevalence of CIDP and the association of diabetes mellitus. Neurology 2009;73(1):39-45.
42. Lindenbaum Y, Kissel JT, Mendell JR. Treatment approaches for Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. Neurologic Clinics 2001;19(1):187-204.
43. Lopate G, Pestronk A, Al-Lozi M. Treatment of chronic inflammatory demyelinating polyneuropathy with high-dose intermittent intravenous methylprednisolone. Archives of Neurology 2005;62(2):249-54.
44. Lunn MP, Manji H, Choudhary PP, Hughes RA, Thomas PK. Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in south east England. Journal of Neurology Neurosurgery & Psychiatry 1999;66(5):677-680.
45. Mahdi-Rogers M, Swan AV, van Doorn PA, Hughes RAC. Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database of Systematic Reviews 2013, Issue 6. [DOI: ]
46. Martin TD. Safety and tolerability of intravenous immunoglobulins. In: Said G editor(s). Treatment of neurological disorders with intravenous immunoglobulins. London: Martin Duntiz, 2000:181-91.
47. Matsumuro K, Izumo S, Umehara F, Osame M. Chronic inflammatory demyelinating polyneuropathy: histological and immunopathological studies on biopsied sural nerves. Journal of the Neurological Sciences 1994;127(2):170-8.
48. McCrone P, Chisholm D, Knapp M, Hughes R, Comi G, et al.Cost-utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy. European Journal of Neurology 2003;10(6):687-94.
49. McLeod JG, Pollard JD, Macaskill P, Mohamed A, Spring P, Khurana V. Prevalence of chronic inflammatory demyelinating polyneuropathy in New South Wales, Australia. Annals of Neurology 1999;46(6):910-913.
50. Hughes RAC, Mehndiratta MM. Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database of Systematic Reviews 2012, Issue 8. [DOI: ]
51. Merkies IS, Schmitz PI, van der Meche FG, van Doorn PA. Psychometric evaluation of a new sensory scale in immune-mediated polyneuropathies. Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Neurology 2000;54(4):943-9.
52. Molenaar DS, Vermeulen M, de Haan R. Diagnostic value of sural nerve biopsy in chronic inflammatory demyelinating polyneuropathy. Journal of Neurology, Neurosurgery & Psychiatry 1998;64(1):84-9.
53. Muley SA, Kelkar P, Parry GJ. Treatment of chronic inflammatory demyelinating polyneuropathy with pulsed oral steroids. Archives of Neurology 2008;65(11):1460-64.
54. Mulrow CD, Oxman AD (eds). Cochrane Collaboration Handbook [updated September 1997]. Cochrane Database of Systematic Reviews 1994, Issue 4.
55. Pollard JD. A critical review of therapies in acute and chronic inflammatory demyelinating polyneuropathies. Muscle & Nerve 1987;10(3):214-21.
56. Rothman KJ. Modern epidemiology. Modern epidemiology. Boston: Little Brown, 1986:177-236.
57. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al.Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
58. Scott OM, Hyde SA, Goddard C, Dubowitz V. Quantitation of muscle function in children: a prospective study in Duchenne muscular dystrophy. Muscle & Nerve 1982;5(4):291-301.
59. Server AC, Lefkowith J, Braine H, McKhann GM. Treatment of chronic relapsing inflammatory polyradiculoneuropathy by plasma exchange. Annals of Neurology 1979;6(3):258-61.
60. Simmons Z, Albers JW, Bromberg MB, Feldman EL. Presentation and initial clinical course in patients with chronic inflammatory demyelinating polyradiculoneuropathy: Comparison of patients without and with monoclonal gammopathy. Neurology 1993;43(11):2202-09.
61. Stiehm ER. Immunoglobulin therapy in primary antibody deficiency and HIV infection. In: Kazatchkine MD, Morell A editor(s). Intravenous immunoglobulin: research and therapy. 1. Pearl River NY: Parthenon Publishing, 1996:193-203.
62. van der Meché FGA, Vermeulen M, Busch HFM. Chronic inflammatory demyelinating polyneuropathy. Brain 1989;112(Pt 6):1563-71.
63. van der Meché FGA, van Doorn PA. Future developments in the treatment of immune-related polyneuropathies. European Neurology 1997;38(3):230-7.
64. van Doorn PA, Rossi F, Brand A, van Lint M, Vermeulen M, Kazatchkine MD. On the mechanism of high-dose intravenous immunoglobulin treatment of patients with chronic inflammatory demyelinating polyneuropathy. Journal of Neuroimmunology 1990;29(1-3):57-64.
65. van Doorn PA, Vermeulen M, Brand A, Mulder PGH, Busch HFM. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy. Archives of Neurology 1991;48(2):217-20.
66. van Nes SI, Faber CG, Merkies IS. Outcome measure in immune-mediated neuropathies: the need to standardize their use and to understand the clinimetric essentials. Journal of the Peripheral Nervous System 2008;13(2):136-47.
67. van Schaik IN, Vermeulen M, Brand A. In vitro effects of polyvalent immunoglobulin for intravenous use. Journal of Neurology, Neurosurgery & Psychiatry 1994;57(Suppl):15-7.
68. van Schaik IN, Eftimov F, van Doorn PA, Brusse E, van den Berg LH, van der Pol WL, et al.Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial. Lancet Neurology 2010;9(3):245-53.
69. Vermeulen M, van der Meché FGA, Speelman JD, Weber A, Busch HFM. Plasma and gamma-globulin infusion in chronic inflammatory polyneuropathy. Journal of the Neurological Sciences 1985;70(3):317-26.
70. Appropriate uses of human immunoglobulin in clinical practice: memorandum from an IUIS/WHO meeting. Bulletin of the World Health Organization 1982;60(1):43-7.
71. Yu Z, Lennon VA. Mechanism of Intravenous Immune Globulin Therapy in Antibody-Mediated Autoimmune Diseases. New England Journal of Medicine 1999;340(3):227-8.